Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Clinical Genitourinary Cancer
|
December 12, 2018
Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib
Maxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 31, 2014
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
Benoit Beuselinck, Diether Lambrechts, Thomas Van Brussel, et al.
BJU International
|
November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib
Benoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Acta Oncologica (Stockholm, Sweden)
|
February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis
Benoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
The Lancet. Oncology
|
October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
Cell
|
July 19, 2018
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, et al.
The New England Journal of Medicine
|
November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinib
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Clinical Genitourinary Cancer
|
December 12, 2018
Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib
Maxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 31, 2014
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
Benoit Beuselinck, Diether Lambrechts, Thomas Van Brussel, et al.
BJU International
|
November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib
Benoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Acta Oncologica (Stockholm, Sweden)
|
February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis
Benoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
The Lancet. Oncology
|
October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
Cell
|
July 19, 2018
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, et al.
The New England Journal of Medicine
|
November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinib
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
Page
of 6